Skip to content

Safety and Efficacy of Foligen TrichoBoost Serum in Hair Growth and hairfall

A Clinical Study to Evaluate the Safety and Efficacy of Foligen TrichoBoost Serum in Hair Growth and Hairfall with Phototrichogram - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/06/112179
Enrollment
36
Registered
2026-06-08
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Test Product: Foligen TrichoBoost Serum: Test Product: Foligen TrichoBoost Serum Dose: Apply approximately 0.5 to 1 ml of the product using a dropper directly onto the scalp. Gently mas

Sponsors

GFCP Private Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Indian / Asian female and male subjects with Norwood Scale Hair loss Stage 2 and 3 2. Healthy subjects (no infectious and evaluative pathology which could make the subject vulnerable and stop the study, no pathology which could interfere with the study, no symptom in the process of an exploratory checkup 3.Between 25 and 45 years of age. 4.Skin is healthy on the studied anatomic unit free of eczema, wounds, inflammatory scar.

Exclusion criteria

Exclusion criteria: 1.Being pregnant or breastfeeding or having stopped to breastfeed in the past three months 2.Having refused to give her assent by not signing the consent form 3.Taking part in another study liable to interfere with this study 4.Having a chronic dermatosis liable to modify the cutaneous reactivity on the tested area 5.Being insulin-dependent diabetic or noninsulin-dependent diabetic with a recent therapy (less than 6 months) 6.Having a progressive asthma (either under treatment or last fit in the last 2 years) 7.Being epileptic 8.Having non stabilized thyroid problems (requirement of a stabilized treatment for at least 6months) 9.Having cutaneous hypersensitivity 10.Having a diagnosed or highly probable allergy to one or several compounds of the cosmetic products 11.Following a chronic or intermittent medicinal treatment comprising any of the following products : aspirin-based products, anti-inflammatories, anti-histamines, anti- coagulants, corticotherapy, taken by general or local routes (the only medication permitted is paracetamol) 12.Having undergone a surgery requiring a general anaesthetic of more than one hour in the past6 months 13.Having changed her cosmetic habits except those required by the protocol in the 14 days preceding the start of the study on the studied anatomic unit 14.Having applied a cosmetic product on the studied areas the first day of the study (except the usual shampoo)

Design outcomes

Primary

MeasureTime frame
1.Change in Hair Density 2.Change in A-T Ratio 3.Change in Hair Thickness 4.Change in Percentage of Vellus Hair 5.Change in Percentage of Terminal hair 6. HD ImagingTimepoint: T0min, T+2 days, T+28 days ,T+30 days, T+56 days, T+58 days, T+84 days and T+86 days

Secondary

MeasureTime frame
1. Change in Subject assessmentTimepoint: At day30, day58, day86

Countries

India

Contacts

Public ContactPuneet Mittal

CCFT Laboratories

puneetmittal@mgcts.org08937015757

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 29, 2026